KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Net Income: 2017-2024

Historic Net Income for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$44.1 million.

  • Aquestive Therapeutics' Net Income fell 34.21% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 96.00%. This contributed to the annual value of -$44.1 million for FY2024, which is 460.83% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Net Income of -$44.1 million as of FY2024, which was down 460.83% from -$7.9 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Net Income high stood at -$7.9 million for FY2023, and its period low was -$70.5 million during FY2021.
  • Its 3-year average for Net Income is -$35.5 million, with a median of -$44.1 million in 2024.
  • Its Net Income has fluctuated over the past 5 years, first surged by 85.54% in 2023, then crashed by 460.83% in 2024.
  • Aquestive Therapeutics' Net Income (Yearly) stood at -$55.8 million in 2020, then decreased by 26.45% to -$70.5 million in 2021, then increased by 22.87% to -$54.4 million in 2022, then surged by 85.54% to -$7.9 million in 2023, then plummeted by 460.83% to -$44.1 million in 2024.